Clinical Impact of Linezolid Therapeutic Drug Monitoring on the Tolerability of Prolonged Courses in the Outpatient Setting
Clicks: 1
ID: 314546
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #159 of 208 articles by views in Open forum infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Structured Abstract Background Linezolid is a gram-positive oral antibiotic whose duration-dependent risk of thrombocytopenia has historically constrained durations of therapy to < 3 weeks. This study aimed to evaluate whether TDM-based management of linezolid can support prolonging the course of therapy for complex infections. Methods This single center, retrospective cohort study included patients > 18 years old discharged on linezolid for a planned duration > 3 weeks between January 1, 2023, and April 1, 2025. The primary outcome was early discontinuation of linezolid due to thrombocytopenia, compared between patients managed with TDM and matched controls without TDM, using 1:1 matching based on planned treatment duration. Results 162 patients were included, with 81 in each study arm. The mean duration of linezolid was 32.1 days (SD +12.4), and 100 (62%) patients were treated for bone and joint infections. Patients receiving TDM were significantly more likely to be ≥ 65 years, have recent surgery, receive Complex Outpatient Antimicrobial Therapy (COpAT) monitoring, have longer inpatient courses, and have additional laboratory monitoring performed. The primary outcome of early discontinuation from thrombocytopenia occurred in 11 (14%) patients versus 25 (31%) patients in the TDM and control arms, respectively (adjusted OR 0.07 [95% CI 0.02–0.26]). Thrombocytopenia remained the most common toxicity in both cohorts. Conclusions Linezolid TDM was associated with markedly lower rates of early discontinuation from thrombocytopenia, underscoring the potential value of early TDM and selective dose adjustment to enhance tolerability during prolonged treatment courses.
| Reference Key |
openalex_W7162008744
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Jeffrey M. Harrington, Jerod Nagel, Samantha Sallerson, Xuping Yan, Samuel L Aitken, Vincent D. Marshall, Beth Lawless, Manjunath P. Pai, J Pogue, Gregory Eschenauer |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag318
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.